Recombinant Human E3 ubiquitin-protein ligase MARCH9 (41342)
Description
Introduction to Recombinant Human E3 Ubiquitin-Protein Ligase MARCH9 (41342)
Recombinant Human E3 ubiquitin-protein ligase MARCH9 (41342) is a protein engineered to mimic the function of the naturally occurring membrane-associated RING-CH-type finger 9 (MARCH9) protein. MARCH9 is an E3 ubiquitin ligase that plays a crucial role in the regulation of immune responses by targeting various membrane proteins for ubiquitination and subsequent degradation or endocytosis. This process is essential for modulating the expression of major histocompatibility complex class I (MHC I) molecules and other immune-related proteins.
Function and Mechanism of MARCH9
MARCH9 functions primarily at the trans-Golgi network (TGN), where it facilitates the ubiquitination of MHC I molecules. This ubiquitination allows MHC I to access Syntaxin 6-positive endosomal compartments, which is crucial for efficient antigen presentation to cytotoxic T cells . Additionally, MARCH9 can target other proteins such as CD1a, a lipid antigen-presentation molecule, and ICAM1, promoting their endocytosis and sorting to lysosomes .
Table 1: Targets of MARCH9 Ubiquitination
| Target Protein | Function/Role |
|---|---|
| MHC I | Antigen presentation to cytotoxic T cells |
| CD1a | Lipid antigen presentation |
| ICAM1 | Cell adhesion and immune response modulation |
| CD4 | T cell receptor complex component |
Role in Immune Regulation
MARCH9's expression is modulated by microbial pattern exposure in dendritic cells (DCs), highlighting its role in coordinating MHC I access to endosomes and DC activation for efficient antigen cross-presentation . This regulation is critical for the adaptive immune response, particularly in the context of viral infections and tumor immunity.
Research Findings and Applications
Research on MARCH9 has provided insights into its potential applications in immunotherapy and vaccine development. By modulating MHC I expression, MARCH9 could influence the efficacy of antigen presentation and T cell activation. Moreover, understanding how MARCH9 regulates immune receptors can help in designing strategies to enhance or suppress immune responses depending on the therapeutic context.
Table 2: Potential Applications of MARCH9 Research
| Application Area | Description |
|---|---|
| Immunotherapy | Modulation of MHC I expression for enhanced antigen presentation |
| Vaccine Development | Optimization of antigen presentation pathways for improved vaccine efficacy |
| Autoimmune Diseases | Potential therapeutic target for modulating immune responses |
Product Specs
Note: While we will prioritize shipping the format currently in stock, please specify your format preference in order notes for customized preparation.
Note: All proteins are shipped with standard blue ice packs unless dry ice is specifically requested in advance. Additional fees apply for dry ice shipping.
If a specific tag type is required, please inform us, and we will prioritize its development.
Target Background
- MARCH9 overexpression attenuated the oncogenic effects of ICAM-1, suggesting a potential role in tumor suppression via ICAM-1 downregulation. PMID: 30278450
- MARCH9-mediated ubiquitination regulates MHC I export from the trans-Golgi network. PMID: 28559542
- Heat shock reversed MARCH9-mediated Mult1 downregulation, indicating dissociation of the two proteins and increased Mult1 cell surface expression. PMID: 20870941
- MARCH9 expression leads to ICAM-1 ubiquitination and downregulation. PMID: 17174307
